O nesiritide reduz mortalidade e reinternação na insuficiência cardíaca descompensada?

Bernardo, Wanderley Marques; Moreira, Fábio Tanzillo

doi:10.1590/s0104-42302012000200005

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nesiritide is now clinically available for the management of acute decompensated HF although no primary endpoint benefit was reported. 72 , 73 However, adopting this approach to treatment in chronic HF has been problematic because of poor oral bioavailability of NPs. 74 …”

Section: Novel Approaches To Myocardial Contractilitymentioning

confidence: 99%

Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies

Bonsu

Owusu

Buabeng

et al. 2016

TCRM

View full text Add to dashboard Cite

Heart failure (HF) is a major public health priority due to its epidemiological transition and the world’s aging population. HF is typified by continuous loss of contractile function with reduced, normal, or preserved ejection fraction, elevated vascular resistance, fluid and autonomic imbalance, and ventricular dilatation. Despite considerable advances in the treatment of HF over the past few decades, mortality remains substantial. Pharmacological treatments including β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists have been proven to prolong the survival of patients with HF. However, there are still instances where patients remain symptomatic, despite optimal use of existing therapeutic agents. This understanding that patients with chronic HF progress into advanced stages despite receiving optimal treatment has increased the quest for alternatives, exploring the roles of additional pathways that contribute to the development and progression of HF. Several pharmacological targets associated with pathogenesis of HF have been identified and novel therapies have emerged. In this work, we review recent evidence from proposed mechanisms to the outcomes of experimental and clinical studies of the novel pharmacological agents that have emerged for the treatment of HF.

show abstract

Section: Novel Approaches To Myocardial Contractilitymentioning

confidence: 99%